Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
about
Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyAdenosine A(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's DiseaseComparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers.Cortical and Striatal Reward Processing in Parkinson's Disease Psychosis.Systematic review of methods used in meta-analyses where a primary outcome is an adverse or unintended eventRotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER).Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label studyUpdate on the use of pramipexole in the treatment of Parkinson's disease.Current approaches to the treatment of Parkinson's diseaseIndirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.The management of orthostatic hypotension in Parkinson's disease.Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson's disease.The benefits of pramipexole selection in the treatment of Parkinson's disease.Pramipexole and its extended release formulation for Parkinson's disease.An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.The impact of rotigotine on cardiovascular autonomic function in early Parkinson's disease.Ropinirole in treatment-resistant depression: a 16-week pilot study.Pramipexole-induced psychosis in Parkinson's disease.Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.
P2860
Q26738349-2F56FF8C-24FF-483F-B191-5BA8EAEBB6ECQ30472044-8FFD0180-B0BC-4995-962A-775EE7B05FBFQ30492844-B3985954-63E2-41C5-A4D0-60F6FD8B6319Q33593735-9A0E544E-1794-4CB7-96DF-80E997DEEEA4Q34254787-B202E27D-09A3-4B25-831E-93D3948C4D94Q34771200-E63A3041-FD85-4E3A-9B41-15CCDFF7A0C9Q35190299-57CE1207-F462-47AC-8265-9BE7DA84F681Q36842189-DC1FF7BD-AE56-493B-AE5D-31564D52E800Q36876438-2A310D9A-625B-4F7C-8DD0-14B5678D0086Q37981266-9DEDEECF-52A7-41DB-A7A6-08EBE6FFB023Q38114882-413FC88D-2881-4B14-89D3-DE5856AA075CQ38223072-B2C2BB00-2D7B-486C-80C6-A80A618C4D45Q38231222-8369CCB1-6254-43A8-89B5-5EFE9B7B8F1EQ41021587-3C22384D-1927-48F7-8BF8-717160D76EE9Q43290028-AE9DD102-6CC8-493D-A4E3-D9E75E72831CQ43976027-8729DC4E-BE2B-4CDA-99B0-6CDD1835091DQ46586074-CAE31963-176B-42E6-928E-714EF74E1CFAQ46644518-6DBFCBBB-5285-4217-A7C2-4A4EDB6CE6D3Q50770517-0B892A52-5717-4605-925B-FB1FC7DF8965
P2860
Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Comparison of the risk of adve ...... on's disease: a meta-analysis.
@ast
Comparison of the risk of adve ...... on's disease: a meta-analysis.
@en
type
label
Comparison of the risk of adve ...... on's disease: a meta-analysis.
@ast
Comparison of the risk of adve ...... on's disease: a meta-analysis.
@en
prefLabel
Comparison of the risk of adve ...... on's disease: a meta-analysis.
@ast
Comparison of the risk of adve ...... on's disease: a meta-analysis.
@en
P2093
P1433
P1476
Comparison of the risk of adve ...... on's disease: a meta-analysis.
@en
P2093
Mahyar Etminan
Sudeep Gill
P304
P356
10.2165/00002018-200326060-00005
P577
2003-01-01T00:00:00Z
P6179
1029379122